Germany's drug shortages leave millions of patients without critical treatments in 2025

Drug shortages in Germany have worsened in 2025, with pharmacies reporting 1,514 supply bottlenecks across 1,041 distinct medicines. The ongoing crisis has left millions of patients without essential treatments, despite efforts to address the issue through legislation. Health insurers now warn that the 2023 Shortages Act has failed to bring lasting improvements to the system.

The latest figures reveal severe shortages in key medication categories. Antibiotics have seen 85 shortage reports, each lasting an average of 122 days and affecting 2.2 million patients. Lipid-lowering agents follow closely, with 89 reports and shortages stretching 156 days, impacting roughly two million people. Antipsychotics remain critically scarce, logging 173 reports and an average shortage duration of 230 days, disrupting treatment for around one million patients.

Antidepressants have also been hit hard, with 130 shortage reports and an average gap of 107 days, leaving another million patients without consistent access. Data from the Federal Institute for Drugs and Medical Devices (BfArM) shows a sharp rise in antidepressant shortages—from 1,248 reports in 2023 to 2,116 in 2024, a 70% increase. Antipsychotic shortages climbed by 46% over the same period, from 312 to 456 reports.

The problem extends beyond these categories. Salbutamol, used for respiratory conditions, and antiepileptic drugs face persistent shortages, compounded by a lack of viable alternatives. Germany's reliance on Asian manufacturing for many drugs and active ingredients leaves its supply chain exposed to global disruptions.

In response, stakeholders are pushing for an early-warning system. The proposal aims to alert German suppliers about major production failures in Asia before shortages reach patients. However, no concrete measures have yet been implemented to prevent future crises.

The ongoing shortages highlight deep vulnerabilities in Germany's pharmaceutical supply chain. With millions of patients affected and no immediate solutions in place, the system remains at risk of further disruptions. Authorities and health providers continue to monitor the situation, but structural fixes have so far remained out of reach.